The use of CLL-IPI, a new prognostic index for CLL
The potential for patient-level data in the NHS
How can the study of familial leukemias help us to understand sporadic leukemias?
Jane E. Churpek
Nivolumab in combination with azacitidine in patients with relapsed acute myeloid leukemia (AML)
Naval G. Daver
Why aren’t cytogenetic analyses being implemented into clinical studies of CLL?